Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Hormonal therapy for prostate cancer: can bicalutamide-induced gynecomastia and breast pain be prevented?

Nature Clinical Practice Urology volume 3, pages 186–187 (2006)Cite this article

boxed-textDi Lorenzo G et al. (2005) Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy. J Urol 174: 2197–2203

Tamoxifen reduces bicalutamide-induced gynecomastia and breast pain, but until the long-term benefits and risks are defined, the use of tamoxifen outside the context of a clinical trial should be discouraged

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Wirth MP et al. (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172: 1865–1870

    Article  CAS  Google Scholar 

  2. Perdona S et al. (2005) Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 6: 295–300

    Article  CAS  Google Scholar 

  3. Saltzstein D et al. (2005) Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 8: 75–83

    Article  CAS  Google Scholar 

  4. Dicker AP (2003) The safety and tolerability of low-dose irradiation for the management of gynaecomastia caused by antiandrogen monotherapy. Lancet Oncol 4: 30–36

    Article  Google Scholar 

  5. Deitcher SR and Gomes MP (2004) The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101: 439–449

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Sandra Ford, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Medical Oncologists at the BC Cancer Agency, Vancouver, Canada

    Jorg Michels & Kim N Chi

  2. Chair of the GU Cancer Systemic Therapy Group at the BC Cancer Agency, the Medical Director of the Clinical Trials Unit of the Vancouver Cancer Centre, and an Assistant Professor of Medicine at the University of British Columbia,

    Jorg Michels & Kim N Chi

Authors
  1. Jorg Michels
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kim N Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kim N Chi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michels, J., Chi, K. Hormonal therapy for prostate cancer: can bicalutamide-induced gynecomastia and breast pain be prevented?. Nat Rev Urol 3, 186–187 (2006). https://doi.org/10.1038/ncpuro0442

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0442

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing